Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Who Should NOT Use BPC-157 Pregnant or breastfeeding women insufficient safety data Active or recent cancer theoretical angiogenesis concern Uncontrolled bleeding disorders Known peptide allergy Uncontrolled severe cardiovascular disease without specialist clearance Drug Interactions Formal interaction data is limited
It addresses multiple skin problems, such as anti-aging, hyperpigmentation, skin whitening, black spots, acne scars, and more
Moreover, we support buyers who need flexible batch planning, consolidated shipments, and clear communication across time zones
The closest safety dataset is the Increlex (mecasermin) clinical program , which followed 71 pediatric patients with severe primary IGFD on twice-daily SubQ rhIGF-1 for a mean of 3.9 years (some patients up to 11.5 years)
The prices are very reasonable and customer service is second to none
